Figure S1, Figure S2, Figure S3, Figure S4, Figure S5 from Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers

Figure S1, Figure S2, Figure S3, Figure S4, Figure S5 from Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers

<p>Supplemental Figures 1 - 5</p>

-д хадгалсан:

Номзүйн дэлгэрэнгүй
Үндсэн зохиолч:	Timothy P. DiPeri (16384177) (author)
Бусад зохиолчид:	Kurt W. Evans (16384180) (author), Maria Gabriela Raso (15107821) (author), Ming Zhao (16384183) (author), Yasmeen Q. Rizvi (16384186) (author), Xiaofeng Zheng (16384189) (author), Bailiang Wang (16384192) (author), Bryce P. Kirby (16384195) (author), Kathleen Kong (16384198) (author), Michael Kahle (16384201) (author), Timothy A. Yap (15028749) (author), Ecaterina E. Dumbrava (16384204) (author), Jaffer A. Ajani (11016306) (author), Siqing Fu (15047712) (author), Khandan Keyomarsi (14958560) (author), Funda Meric-Bernstam (10258780) (author)
Хэвлэсэн:	2025
Нөхцлүүд:	Cancer Molecular and Cellular Biology Therapeutic Research and Development Methods and Technology DNA Damage and Repair Gastrointestinal Cancers Preclinical Models Translational Research
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!

Ижил төстэй зүйлс

Figures S1-S2 from Preclinical and Clinical Efficacy of Trastuzumab Deruxtecan in Breast Cancer Brain Metastases
-н: Sheheryar Kabraji (15050565)
Хэвлэсэн: (2025)

Figure 2 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
-н: Nigel Bundred (15046233)
Хэвлэсэн: (2025)

Figure 1 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
-н: Nigel Bundred (15046233)
Хэвлэсэн: (2025)

Figure 3 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
-н: Nigel Bundred (15046233)
Хэвлэсэн: (2025)

Figure S2 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
-н: Jamunarani Veeraraghavan (16461809)
Хэвлэсэн: (2025)

Figure S1 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
-н: Jamunarani Veeraraghavan (16461809)
Хэвлэсэн: (2025)

Figure S3 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
-н: Jamunarani Veeraraghavan (16461809)
Хэвлэсэн: (2025)

Figure S4 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
-н: Jamunarani Veeraraghavan (16461809)
Хэвлэсэн: (2025)

Figure S5 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
-н: Jamunarani Veeraraghavan (16461809)
Хэвлэсэн: (2025)

Figure S6 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
-н: Jamunarani Veeraraghavan (16461809)
Хэвлэсэн: (2025)

Supplementary Figure S2 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
-н: Javier Pascual (15018176)
Хэвлэсэн: (2025)

Figure S2 from The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma
-н: Sebastian Johannes Schober (14971891)
Хэвлэсэн: (2025)

Table 2 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
-н: Nigel Bundred (15046233)
Хэвлэсэн: (2025)

Supplemental Figure S2 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance
-н: Jennifer L. Cotton (17315204)
Хэвлэсэн: (2025)

Supplementary Figure S1 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
-н: Javier Pascual (15018176)
Хэвлэсэн: (2025)

Supplementary Figure S3 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
-н: Javier Pascual (15018176)
Хэвлэсэн: (2025)

Supplementary Figure S4 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
-н: Javier Pascual (15018176)
Хэвлэсэн: (2025)

Supplementary Figure S5 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
-н: Javier Pascual (15018176)
Хэвлэсэн: (2025)

Figure 2 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
-н: Milana A. Bergamino (15038015)
Хэвлэсэн: (2025)

Supplementary Table S2 from Caffeine Supplementation and FOXM1 Inhibition Enhance the Antitumor Effect of Statins in Neuroblastoma
-н: Gia-Buu Tran (16437051)
Хэвлэсэн: (2025)

Table 1 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
-н: Nigel Bundred (15046233)
Хэвлэсэн: (2025)

Figure 1 FS1 from FGFR mRNA Expression in Cholangiocarcinoma and Its Correlation with <i>FGFR2</i> Fusion Status and Immune Signatures
-н: Vishwajith Sridharan (15047154)
Хэвлэсэн: (2025)

Table S2 from Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma
-н: Alyssa C. Flint (16676029)
Хэвлэсэн: (2025)

Supplementary Figure S2 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
-н: Ulka N. Vaishampayan (15051039)
Хэвлэсэн: (2025)

Figure S.2 from Loss of LOXL2 Promotes Uterine Hypertrophy and Tumor Progression by Enhancing H3K36ac-Dependent Gene Expression
-н: Xufeng Lu (14960724)
Хэвлэсэн: (2025)

Figure S1 from The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma
-н: Sebastian Johannes Schober (14971891)
Хэвлэсэн: (2025)

Figure S3 from The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma
-н: Sebastian Johannes Schober (14971891)
Хэвлэсэн: (2025)

Figure S4 from The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma
-н: Sebastian Johannes Schober (14971891)
Хэвлэсэн: (2025)

Figure S5 from The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma
-н: Sebastian Johannes Schober (14971891)
Хэвлэсэн: (2025)

Supplementary Figure S2 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer
-н: Carlotta Antoniotti (15352506)
Хэвлэсэн: (2025)

Supplementary Tables from Therapy-Induced Senescence Enhances the Efficacy of HER2-Targeted Antibody–Drug Conjugates in Breast Cancer
-н: Santiago Duro-Sánchez (14959182)
Хэвлэсэн: (2025)

Table S5 from Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma
-н: Alyssa C. Flint (16676029)
Хэвлэсэн: (2025)

Supplementary Figure S1 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
-н: Ulka N. Vaishampayan (15051039)
Хэвлэсэн: (2025)

Supplementary Figure S3 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
-н: Ulka N. Vaishampayan (15051039)
Хэвлэсэн: (2025)

Supplemental Figure S1 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance
-н: Jennifer L. Cotton (17315204)
Хэвлэсэн: (2025)

Supplemental Figure S3 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance
-н: Jennifer L. Cotton (17315204)
Хэвлэсэн: (2025)

Supplemental Figure S4 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance
-н: Jennifer L. Cotton (17315204)
Хэвлэсэн: (2025)

Supplemental Figure S5 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance
-н: Jennifer L. Cotton (17315204)
Хэвлэсэн: (2025)

Supplemental Figure S6 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance
-н: Jennifer L. Cotton (17315204)
Хэвлэсэн: (2025)

Supplemental Figure S7 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance
-н: Jennifer L. Cotton (17315204)
Хэвлэсэн: (2025)

Cannot write session to /tmp/vufind_sessions/sess_oar0rc0bdrup9fkln0l5pr0red